Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HL-300 Ointment After Single and Multiple Doses in Healthy Adult Volunteers

NCT07684937 is registered in ClinicalTrials.gov with Hangzhou Highlightll Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07684937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HL-300 Ointment After Single and Multiple Doses in Healthy Adult Volunteers
Lead sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
June 14, 2024
Completion date
November 25, 2024
Enrollment
36 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis